The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
 
Jaleh Fallah
No Relationships to Disclose
 
C. Marcela Diaz-Montero
No Relationships to Disclose
 
Patricia A. Rayman
No Relationships to Disclose
 
Wei (Auston) Wei
No Relationships to Disclose
 
Laura S. Wood
Consulting or Advisory Role - Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
 
Allison Martin
No Relationships to Disclose
 
Kimberly D Allman
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Exelixis; Pfizer; Sanofi
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - WellPoint
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Exelixis
Travel, Accommodations, Expenses - Exelixis
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Merck; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Pfizer; Sanofi
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer